Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Kyle Schneweis

Sports Medicine Liberty, MO Medical Doctor

NPI 1174834378 CMS profile 710520

2609 Glenn Hendren Dr, Liberty, MO 64068

Open in the dashboard

General payments

$568

45 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Kyle Schneweis of Liberty, MO is reported in the CMS Open Payments database as having received $568 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $105 8
2019 General $462 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyle Schneweis
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Kyle Schneweis were reported at $0. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Kyle Schneweis Sports Medicine median Middle half National median
2019 $462 $119 $35–$362 $163
2020 $105 $77 $24–$275 $114
2021 $0 $104 $28–$340 $132
2022 $0 $94 $31–$272 $149
2023 $0 $91 $34–$271 $160
2024 $0 $126 $38–$294 $164
2025 $0 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Lilly USA, LLC $136 14 payments
  2. Amgen Inc. $77 5 payments
  3. Cranial Technologies, Inc $45 4 payments
  4. Genentech USA, Inc. $43 3 payments
  5. Grifols USA, LLC $43 2 payments
  6. Novo Nordisk Inc $40 3 payments
  7. Sanofi-Aventis U.S. LLC $37 3 payments
  8. Pfizer Inc. $33 3 payments
  9. Allergan Inc. $20 1 payment
  10. Fidia Pharma USA Inc. $18 1 payment
  11. Other $76 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $568 45 payments
Products named General payments · program years 2019–2020
  1. TRULICITY $94 10 payments
  2. JARDIANCE $83 9 payments
  3. BASAGLAR $83 9 payments
  4. Prolia $65 4 payments
  5. EVENITY $47 3 payments
  6. Doc Band $45 4 payments
  7. Xofluza $43 3 payments
  8. EMGALITY $43 4 payments
  9. Prolastin-C Liquid $43 2 payments
  10. Ozempic $40 3 payments
  11. Other $270 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 118 drugs

Part D claims

6,304

Median for Family Practice: 1,826

Drug cost

$349,708

Median for Family Practice: $120,094

Branded share of claims

19.8%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 111 $83,108
Jardiance Empagliflozin Brand 78 $47,490
Linzess Linaclotide Brand 33 $22,659
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 20 $17,276
Tresiba Flextouch U-100 Insulin Degludec Brand 17 $16,513
Januvia Sitagliptin Phosphate Brand 52 $16,465
Ozempic Semaglutide Brand 14 $15,505
Myrbetriq Mirabegron Brand 50 $11,221
Breo Ellipta Fluticasone/Vilanterol Brand 15 $9,159
Varenicline Tartrate Generic 34 $8,716

The 10 drugs with the highest cost, of 118 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$56,717

Of which drugs: $20,128

Medicare patients

243

Average age 73

Services billed

6,591

112 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 53%
Ischemic heart disease 30%
Diabetes 26%
Depression 19%
Atrial fibrillation 17%
Chronic kidney disease 16%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 13 13 $3,769
Sarscv2 vac 30mcg trs-suc im 91320 Office 21 22 $3,087
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 23 23 $1,882
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 72 518 $375

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record